Laman UtamaB9P0 • FRA
add
NovaBay Pharmaceuticals Inc
Tutup sebelumnya
€2.80
Julat tahun
€2.80 - €2.80
Permodalan pasaran
3.43J USD
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 2.70J | -19.73% |
Pendapatan bersih | 7.67J | 338.64% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | — | — |
EBITDA | -2.70J | -73.12% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 8.47J | 364.45% |
Jumlah aset | 9.87J | 84.28% |
Jumlah liabiliti | 3.70J | -28.71% |
Jumlah ekuiti | 6.17J | — |
Syer tertunggak | 5.82J | — |
Harga kepada buku | — | — |
Pulangan pada aset | -101.58% | — |
Pulangan pada modal | -152.86% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 7.67J | 338.64% |
Tunai daripada operasi | 9.74J | 648.09% |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | -1.71J | -186.10% |
Perubahan bersih dalam tunai | 8.04J | 714.92% |
Aliran tunai bebas | 26.88K | -98.06% |
Perihal
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.
and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Diasaskan
2000
Ibu pejabat
Tapak web
Pekerja
14
